Rare Mutations and Fusions Patient Gateway
About rare mutations and fusions in lung cancer
Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
LATEST UPDATES
-
Research Milestones: Celebrating LUNGevity’s 2024 Research Awards
LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in... -
Brain Mets Basics for NSCLC: What Are Brain Metastases and How Do We Treat Them?
Read time: 2 minutes. Brain metastases (also called brain mets) develop when cancer from somewhere else in the body spreads to the brain. Over time, tumors can become metastatic... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Sponsors
